Long-term observational study of Gene Therapy for Parkinson's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2033220367

Enrollment

Registered

2022-10-07

Start date

2022-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Patients who enrolled in the Phase I/II Study of Gene Therapy for Parkinson's disease, and who completed or discontinued the study.

Exclusion criteria

Exclusion criteria: -Patients who cannot undergo MRI. -Individuals who wish to have children, but do not cryopreserve sperm or eggs prior to administration of the investigational product and use them to obtain children.

Design outcomes

Primary

Measure	Time frame
To investigate the long-term tolerability, safety, and efficacy of the study product in patients with Parkinson's disease, after intracerebral administrations of AAV-hAADC-2 into the putamen.	—

Contacts

Public ContactShinya Sekiguchi

SRD, Inc.

pd_gt0002x-11@cro-srd.co.jp+81-3-5543-0306

Outcome results